Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-24 @ 2:49 PM
Ignite Modification Date:
2025-12-24 @ 2:49 PM
NCT ID:
NCT07283159
Eligibility Criteria:
Inclusion Criteria:
* Age ≥ 18 year;
* Acute ischemic stroke confirmed by neuroimaging;
* The time from last known well to treatment is within 4.5 hours;
* NIHSS ≥ 6 at randomization;
* Received intravenous tenecteplase (0.25mg/kg);
* First stroke onset or past stroke without obvious neurological deficit (mRS≤1);
* Signed informed consent.
Exclusion Criteria:
* Planed for endovascular treatment;
* Use of Edaravone Injection, Edaravone Dexborneol Injection, Butylphthalide Injection or Capsules after the onset of the current episode；
* Prior use of ACE inhibitors within a period less than 5 half-lives before the intended administration of Urinary Kallidinogenase for Injection；
* Pregnancy；
* Allergy to the investigational drug(s)；
* Comorbidity with other serious diseases;
* Participating in other clinical trials within 3 months;
* Patients not suitable for the study considered by researcher.
Healthy Volunteers:
False
Sex:
ALL
Minimum Age:
18 Years
Study:
NCT07283159
Study Brief:
Protocol Section:
NCT07283159